DEA Just Banned Three Synthetic Opioids Stronger Than Fentanyl. Why New York Should Pay Attention.
Federal regulators classified butonitazene, flunitazene, and metodesnitazene as Schedule I drugs after overdose deaths linked to the ultra-potent opioids spread across the U.S.
On March 11, 2026, the Drug Enforcement Administration formally moved three synthetic opioids into Schedule I of the Controlled Substances Act — the category reserved for drugs with no accepted medical use and high abuse potential.
The substances are butonitazene, flunitazene, and metodesnitazene, all members of the nitazene class. You probably haven't heard these names. That's part of the problem.
Nitazenes don't show up on standard drug tests. They're being mixed into counterfeit pills, heroin, and cocaine. And according to toxicology research, they're between 20 and 40 times more potent than fentanyl.
For New York — a state that just recorded its lowest overdose death toll since before COVID — this is more than a regulatory footnote. It's a warning.
What Are Nitazenes?
Nitazenes are a family of synthetic opioids originally developed in the 1950s and 1960s as potential painkillers but never approved for medical use. They resurfaced in illicit drug markets in the late 2010s and have been spreading quietly ever since.
Unlike fentanyl and its analogues, nitazenes have a different chemical structure. That structural difference means two things: they're extraordinarily potent, and they evade detection on many routine toxicology screens used by coroners, hospitals, and harm reduction programs.
The DEA's March 11 action targets three specific nitazenes:
| Substance | Street Presence | Potency vs. Fentanyl |
|---|---|---|
| Butonitazene | Detected in counterfeit pills, heroin | ~20x more potent |
| Flunitazene | Found in powder cocaine, fake Xanax | ~20x more potent |
| Metodesnitazene | Mixed with fentanyl in street heroin | ~40x more potent |
These numbers aren't hypothetical. In animal studies and post-mortem toxicology, researchers have found that microscopic doses — amounts smaller than a grain of salt — can cause fatal respiratory depression.
Dr. Alex Krotulski, a forensic toxicologist who tracks novel opioids at the Center for Forensic Science Research and Education, put it bluntly in a September 2025 interview: "These drugs are designed to be potent. They were never intended for street use, and when they enter the illicit supply, the margin for error disappears."
Why Standard Drug Tests Miss Them
Most hospital emergency departments and coroner's offices use immunoassay tests designed to detect morphine, heroin, and fentanyl. Nitazenes don't trigger these tests because their molecular structure doesn't match the antibodies used in the screening.
That creates a dangerous lag. If a person overdoses on a nitazene-laced pill and is revived with naloxone, the standard toxicology screen might come back negative for opioids — or positive only for fentanyl if both were present. Public health officials won't know nitazenes are circulating in that area until specialized mass spectrometry testing is done, which is expensive and not routine.
A February 2026 study from the UK found that nitazenes degrade rapidly in biological samples, meaning that even when specialized tests are used, the substance may have broken down by the time the sample reaches the lab. Researchers estimated that nitazene deaths could be underreported by as much as one-third.
In the U.S., the Center for Forensic Science Research confirmed that nitazene detections increased sharply from 2019 through 2024, with most cases involving polysubstance mixtures: fentanyl, cocaine, benzodiazepines, or xylazine combined with one or more nitazenes.
According to federal data, at least 320 overdose deaths in 2023 were linked to nitazenes. But experts believe the real number is higher.
The New York Connection
New York made national headlines in February 2026 when Governor Hochul announced a 32 percent drop in overdose deaths for 2025 — the lowest toll since before the pandemic. The state credited expanded naloxone distribution, mobile medication units, and increased access to buprenorphine through telehealth.
Nitazenes threaten to reverse that progress.
In September 2025, Frank Tarentino, special agent in charge of the DEA's New York division, warned that nitazenes were beginning to appear in the city's drug supply. "Fentanyl has been the primary driver of overdose deaths and poisonings," he said at a press briefing, "but now we're seeing a new compound — nitazene — on our streets."
At the time, NYPD had seized pills containing isotonitazene and metonitazene, two other nitazene variants, in Manhattan and Brooklyn. Those substances are already Schedule I; the March 2026 action extends the ban to three additional analogues that have since surfaced.
The concern isn't just New York City. Upstate regions — where opioid settlement funds are being deployed to open new treatment programs — are seeing counterfeit prescription pills enter circulation through the same distribution networks that moved fentanyl-laced heroin in prior years.
Dr. Ross Sullivan, an addiction medicine specialist at Upstate Medical University in Syracuse, told reporters in late 2025 that his emergency department had treated multiple suspected nitazene overdoses based on clinical presentation, even though confirmatory testing wasn't available. "These patients required higher doses of naloxone and longer observation periods," he said. "It's a pattern we're watching closely."
What Schedule I Means in Practice
Placing butonitazene, flunitazene, and metodesnitazene in Schedule I doesn't make them disappear. It does three things:
Criminal penalties increase. Manufacturing, distributing, or possessing these substances now carries the same federal penalties as heroin or LSD: up to 20 years for trafficking, with enhancements if death or serious injury results.
Law enforcement gets clearer authority. Before scheduling, prosecutors had to rely on analogue statutes, which require proving that a substance is "substantially similar" to a controlled drug. Now it's explicitly illegal.
Research becomes harder. Schedule I classification requires special DEA licenses for research, which can slow the development of rapid detection tests or clinical studies on how to reverse nitazene overdoses.
Critically, scheduling doesn't affect people who unknowingly consume these drugs. The user who buys what they think is oxycodone and gets a nitazene-laced counterfeit is not committing a federal crime for possession — but they are at extreme risk.
Why Naloxone Still Works (But You May Need More)
Nitazenes are opioids. That means naloxone (Narcan) can reverse their effects by blocking opioid receptors in the brain and restoring breathing.
But because nitazenes bind to receptors more tightly than fentanyl, and because they're present in such small, potent amounts, reversing a nitazene overdose often requires multiple doses of naloxone and extended monitoring.
The New York State Department of Health updated its standing naloxone order in late 2025 to explicitly address this. Pharmacists dispensing naloxone are now advised to:
- Provide two or more doses per kit
- Instruct recipients that if one dose doesn't work within 3 minutes, administer a second
- Call 911 immediately, even if the person wakes up
Dr. Chinazo Cunningham, who leads the Division of General Internal Medicine at Montefiore Medical Center in the Bronx, emphasized this in a February 2026 interview: "Naloxone works on nitazenes. But people need to know that revival might take longer, and the person might slip back into overdose after the naloxone wears off. Staying with them and getting EMS on scene is critical."
What This Means for Harm Reduction Programs
New York's harm reduction organizations — syringe exchanges, overdose prevention centers, and street outreach teams — are on the front lines of this threat.
OnPoint NYC, which operates the nation's first sanctioned overdose prevention centers, reported in early 2026 that staff had reversed overdoses requiring four or more doses of naloxone, a pattern consistent with ultra-potent synthetic opioids. The organization has called for expanded access to fentanyl test strips (which don't detect nitazenes) and investment in field-deployable mass spectrometry devices that can identify novel substances in real time.
Currently, no low-cost, point-of-use test exists for nitazenes. That puts harm reduction workers, paramedics, and people who use drugs in a position of managing risk without full information.
Dr. Krotulski's group has been working with BTNX, a Canadian company that makes drug checking supplies, to develop immunoassay strips for nitazenes. But as of March 2026, no product is commercially available.
Until that changes, harm reduction messaging in New York has shifted to assume that any illicit opioid — pill, powder, or pressed tablet — could contain nitazenes, fentanyl, xylazine, or all three.
The Regulatory Arms Race
The DEA has been using emergency scheduling powers to ban new synthetic opioids since the fentanyl analogue crisis began in earnest around 2015. Nitazenes are the latest iteration.
The problem is structural. Underground chemists synthesize new analogues faster than regulators can schedule them. By the time butonitazene, flunitazene, and metodesnitazene were banned on March 11, two other nitazene variants — N-pyrrolidino metonitazene and N-pyrrolidino protonitazene — had already been detected and were placed under temporary emergency scheduling the same week.
China, which has been a major source of precursor chemicals for fentanyl production, announced controls on nitazene production in July 2025. The impact of that policy won't be clear for months, and enforcement remains inconsistent.
In the meantime, New York and other states are left managing the downstream effects: overdoses, coroner backlogs, strained treatment capacity, and public confusion.
What Should New Yorkers Do?
If you use drugs:
- Assume any pill, powder, or substance bought outside a pharmacy could contain nitazenes or fentanyl
- Carry naloxone, and make sure people around you know where it is
- Use with someone else present, or use at an overdose prevention center if available
- Start with a very small amount to gauge potency
- If you feel unusually sedated or short of breath, get help immediately
If you work in healthcare, harm reduction, or emergency services:
- Expect to administer multiple naloxone doses
- Monitor patients longer, even after successful revival
- Advocate for access to advanced toxicology testing
- Share information about nitazenes with colleagues and community partners
If you're a family member or concerned community member:
- Learn how to use naloxone (free trainings are available through OASAS and local health departments)
- Keep naloxone at home — it doesn't expire for 2-3 years and could save a life
- Push for policies that expand drug checking, supervised consumption spaces, and rapid access to buprenorphine
The Bigger Picture
Butonitazene, flunitazene, and metodesnitazene are now Schedule I. That won't stop the next analogue from being synthesized, shipped, and mixed into the drug supply.
What it does is buy time — time for toxicologists to develop better tests, time for harm reduction programs to adapt their protocols, and time for policymakers to recognize that enforcement alone won't solve this.
New York's 32 percent drop in overdose deaths in 2025 didn't happen because fentanyl became less dangerous. It happened because the state invested in naloxone, treatment, and harm reduction at scale.
Nitazenes are the next test of that strategy. If New York responds the same way — with evidence, resources, and a commitment to keeping people alive — the state can weather this wave.
If not, the progress of 2025 could vanish as quickly as it came.
Written by
MTNYC Editorial TeamThe MTNYC Editorial Team is a group of healthcare writers, researchers, and addiction specialists dedicated to providing accurate, compassionate, and evidence-based information about addiction treatment and recovery resources in New York State.
